Indaptus Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Indaptus Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.85M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($15.02M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($15.42M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($14.32M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($7.71M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($3.58M) | Mar 21, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($19.83M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($15.37M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($16.38M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($14.91M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($7.73M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($3.60M) | Mar 21, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.34M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $7.25M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $7.62M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $6.32M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $2.52M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.66M | Mar 21, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.82M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($12.32M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($13.41M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($13.08M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($11.29M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($3.32M) | Mar 21, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $3.9K | Mar 17, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.31M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $7.34M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $14.92M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $28.06M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $40.58M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.78M | Mar 21, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.39M | Mar 13, 2025 |
| FY2024 | Dec 31, 2023 | $2.85M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $3.43M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $4.68M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.02M | Mar 21, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.15M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $3.94M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $12.08M | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | $24.63M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $35.90M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | ($237.7K) | Mar 17, 2023 |
| FY2021 | Dec 31, 2019 | $3.21M | Mar 21, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($81.29M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($60.44M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($45.42M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($29.99M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($15.67M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($7.96M) | Mar 21, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.51M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $5.79M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $13.36M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $9.63M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $39.13M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.64M | Mar 21, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (21) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (44) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 17, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (21) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (44) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 13, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.17M | Mar 17, 2026 |
| FY2025 | Jun 27, 2025 | 604,963 | Mar 17, 2026 |
| FY2025 | Jun 26, 2025 | 16.95M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 428,799 | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 8.40M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 8.40M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 8.26M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | 1.94M | Mar 21, 2022 |